MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin ... B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Discover Qartemi, India's innovative CAR-T cell therapy for B-cell Non-Hodgkin Lymphoma, offering personalized and affordable ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

Non-Hodgkin lymphoma is a cancer that affects lymphocytes, a type of white blood cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade ...

Ongoing strength in the U.S. economy drove mortgage rates up over 7% for the first time in eight months, casting doubt over a recovery in the housing sector. The 30-year mortgage rate inched up to ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

Results of 3 trials revealed that omitting transplant did not impact progression or survival outcomes for pediatric, ...

Leukemias and lymphomas are often grouped together because they are both blood-related cancers that originate in lymphocytes. However, leukemia originates in the bone marrow and spreads through the ...